<DOC>
	<DOCNO>NCT03069937</DOCNO>
	<brief_summary>The purpose study look patient outcome docetaxel start prior ADT degarelix .</brief_summary>
	<brief_title>Phase II Study Docetaxel Before Degarelix Patients With Newly Diagnosed Metastatic Prostate Cancer .</brief_title>
	<detailed_description>This study look two drug , docetaxel degarelix , FDA approve treatment prostate cancer . Docetaxel standard chemotherapy treatment metastatic prostate cancer . Degarelix androgen deprivation therapy ( ADT ) agent decrease amount testosterone body , help fight tumor growth . Usually , docetaxel give ADT . This study look cancer change docetaxel start ADT . You ask participate study metastatic prostate cancer treat docetaxel ADT .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histological cytological diagnosis adenocarcinoma prostate . Metastatic disease identify via radiographic assessment CT scan chest , abdomen , pelvis , nuclear bone scan . MRI may use deem necessary investigator . See section 8.5 detail radiographic assessment requirement . More specifically , patient must least one follow time study enrollment : Any visceral metastasis identify CT scan MRI . Site ( ) bony metastasis identify nuclear bone scan , MRI , and/or CT scan . Lymph node base disease consider within single radiation therapy port ( e.g . aortic bifurcation . ) Noncastrate testosterone level , &gt; 50 ng/dl , study enrollment . Age great equal 18 year . ECOG performance status 02 . Meet follow hematologic criterion within 14 day enrollment trial : Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 8.0 g/dl ( may transfuse ) Platelet count &gt; 100,000 mm3 Have adequate endorgan function define follow parameter . All lab value must obtain within 14 day enrollment trial : Creatinine clearance &gt; 30 ml/min . Creatinine clearance determine CockcroftGault formula ( Appendix A ) AST &lt; 2 x institutional ULN ALT &lt; 2 x institutional ULN Total bilirubin &lt; institutional ULN aPTT , PT INR &lt; 1.5 x institutional ULN ( unless therapeutic anticoagulation ) . Agree use barrier method birth control docetaxel portion protocol least one month last docetaxel administration . Informed must sign give write informed consent accordance institutional federal guideline . CNS metastasis ( brain leptomeningeal ) . Osseous metastasis felt opinion clinician highrisk impend pathologic fracture spinal cord compression . Active cardiac disease define symptomatic congestive heart failure , history NYHA Class III IV Heart Failure , uncontrollable supraventricular arrhythmia , history ventricular arrhythmia , active angina pectoris , myocardial infarction coronary intervention within 6 month registration . Prior malignancy require systemic therapy within last 5 year except treat basal squamous cell skin cancer . History lowgrade malignancy limit potential progress determine primary investigator may enrol . Subjects must receive previous androgen deprivation therapy ( LHRH agonist LHRH antagonist ) cytotoxic therapy prostate cancer metastatic setting .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>